Table 3.
Spearman’s correlations between SF-36 scores and clinical and therapeutic features of DTC in Tunisian survivors.
| SF-36 domains | PF | RP | RE | VT | MH | SF | BP | GH |
|---|---|---|---|---|---|---|---|---|
| Age at diagnosis | -0.219* | -0.351* | -0.259* | -0.092 | -0.155 | -0.244* | -0.216* | -0.033 |
| Age at evaluation | -0.303* | -0.327* | -0.245* | -0.055 | -0.028 | -0.214* | -0.094 | -0.073 |
| DTC survivorship | -0.133 | -0.013 | -0.033 | 0.015 | 0.217* | -0.065 | 0.181 | -0.092 |
| RAI cumulative dose | -0.136 | -0.028 | 0.010 | 0.137 | 0.174 | 0.146 | 0.218* | -0.022 |
| Suppressed TSH at evalution | -0.133 | -0.168 | -0.197 | -0.212 | -0.364* | -0.280* | -0.229 | -0.134 |
DTC, Differenciated thyroid cancer; SF-36, Short Form 36 health survey; PF, Physical Functioning; RP, Role-Physical; RE, Role-Emotional; VT, Vitality; MH, Mental Health; SF, Social Functioning; BP, Bodily Pain; GH, General Health; RAI, Radioactive iodine 131; TSH, Thyroid-stimulating hormone.
*statistically significant correlation p<0.05.The bold values represent the statistically significant results.